P. Viens, MD; A. Thyss, MD; G. Garnier, MD; P. Ayela, MD; M. Lagrange, MD; M. Schneider, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is currently proposed as a means for accelerating hematopoietic recovery after aplasia-inducing chemotherapy (1, 2) and as an agent for treating myelodysplasias (3). The various side effects described are rarely of a metabolic nature. We report a case of severe acute hypokalemia in a patient treated with GM-GSF.
A 79-year-old woman was hospitalized for GM-CSF treatment (GM-CSF obtained from Cho-Cell, Sandoz Pharmaceuticals, Basel, Switzerland) because of refractory anemia with excess blast cells as defined by the FAB (French American British Cooperative) requiring erythrocyte transfusions every 4 weeks (randomized study of the Leukemia group
Viens P, Thyss A, Garnier G, et al. GM-CSF Treatment and Hypokalemia. Ann Intern Med. 1989;111:263. doi: https://doi.org/10.7326/0003-4819-111-3-263_1
Download citation file:
Published: Ann Intern Med. 1989;111(3):263.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use